REGISTER
Why This CAR-T Dared to Target Solid Tumors: An Interview with CARsgen’s Zonghai Li
In June 2026, satricabtagene autoleucel became the world’s first CAR‑T product approved for solid tumors—CLDN18.2‑positive advanced gastric/GEJ adenocarcinoma. In this interview, CARsgen founder Zonghai Li discusses the design logic behind the therapy, the “surgery + CAR‑T” strategy showing curative potential, and the company’s strategic pivot toward universal and in vivo CAR‑T platforms.

In June 2026, a CAR‑T cell therapy product named satricabtagene autoleucel was approved in China for the treatment of CLDN18.2‑positive, HER2‑negative advanced gastric/gastroesophageal junction adenocarcinoma that has failed at least two prior lines of therapy. This is the world’s first CAR‑T product approved for solid tumor treatment, and marks the first time that a Chinese innovative drug has truly transitioned from “following” to “leading” in the field of solid tumor CAR‑T. In this regard, MedJ conducted an exclusive interview with Dr. Zonghai Li, co‑founder, chairman, and CEO of CARsgen Therapeutics.

Reflecting on the journey of satricabtagene autoleucel from R&D to approval, Dr. Li repeatedly used the metaphor of “fighting a war”—concentrating superior forces, finding a breakthrough, and fighting a battle of annihilation. Behind this way of speaking is a scientist who emerged from the laboratory and, over more than a decade, turned a technical direction that had barely been validated by anyone into a reality, step by step.

From Hematologic to Solid Tumors: A Fresh Start

CAR‑T therapy first achieved success in hematologic malignancies, but translating it to solid tumors is almost like starting over. Dr. Li likens this to “two different battlefields”: T cells are themselves part of the blood system, making it relatively easy to find hematologic tumors such as lymphoma and myeloma. Solid tumors, however, are completely different—they are more like a structurally complex fortress, with large amounts of fibrous and connective tissue inside. CAR‑T cells need to infiltrate solid tumors and also face a microenvironment that is hypoxic and otherwise unfavorable for T cell survival.

To break through this “city wall,” the team made a key modification to the lymphodepletion preconditioning regimen. The standard preconditioning for hematologic tumors typically uses fludarabine combined with cyclophosphamide, but Dr. Li’s team added nab‑paclitaxel to this regimen. Nab‑paclitaxel is already approved for pancreatic cancer, and taxanes are also used in gastric cancer treatment, indicating that this class of drugs has inherent activity against relevant tumors and, theoretically, can also improve the tumor microenvironment and break through the “iron walls”of solid tumors. The team administers a low dose of nab‑paclitaxel one to two days before CAR‑T infusion to precondition the tumor, followed by cell infusion. This regimen has been patented internationally.

For target selection, the team chose CLDN18.2—a target expressed only on normal gastric epithelial cells, but not on normal gastric stem cells, which leaves room for safety design. Dr. Li explained that the team conducted risk scenario simulations at the design stage. For example, regarding the most concerning risk of gastric perforation: they reasoned that the gastric wall has six layers of structure, making perforation theoretically unlikely; moreover, even if injury occurred, the presence of normal gastric stem cells would facilitate rapid tissue repair. These projections ultimately had to be verified in clinical practice.

There was also a key breakthrough in CAR structural design. Early CAR‑T designs were relatively simple, loading the antibody directly onto the CAR, but this tended to cause CAR molecules to aggregate on the cell surface, generating tonic signaling that led to premature T cell exhaustion. Dr. Li’s team modified the antibody to reduce CAR aggregation. This design concept was later published as a paper and represented the team’s first‑in‑industry solution for reducing T cell exhaustion.

The Life Metrics Hidden in the Data

Technical breakthroughs ultimately must translate into patient benefit. The patient who left the deepest impression on Dr. Li was one whose tumor recurred at the anastomosis between the intestine and esophagus after total gastrectomy. The tumor extended nearly 20 cm upward along the esophagus, almost completely blocking the esophagus—the patient could not even swallow water. One month after receiving satricabtagene autoleucel, the tumor had largely regressed, the patient was able to eat again, and quality of life improved fundamentally, with the response lasting approximately 8 months.

The pivotal phase 2 clinical data for satricabtagene autoleucel provided strong support for the product’s approval (CT041‑ST‑01, NCT04581473): as of October 18, 2024, compared with patients who did not receive satricabtagene autoleucel (investigator‑selected therapy), the median overall survival for all patients receiving satricabtagene autoleucel reached 9.17 months, and the risk of disease progression or death was reduced by more than 70%. These numbers represent tangible survival extension.

What excites Dr. Li even more than the technical breakthrough is the “curative” potential shown by combining CAR‑T with local therapy and surgery. He discussed the team’s ongoing research on first‑line sequential therapy for gastric cancer and postoperative adjuvant therapy: among the 5 first‑line patients already reported (CT041‑CG4006, NCT03874897), 2 achieved surgical conversion after CAR‑T therapy, with one surviving over 51 months and another reaching 58 months. For postoperative adjuvant therapy patients (CT041‑CG4010, NCT06857786), enrollment began in May 2025, and as of the announcement date (July 15, 2026), none of the participants receiving satricabtagene autoleucel had experienced postoperative recurrence or metastasis of gastric cancer. This suggests a possibility: through local therapy such as surgery combined with CAR‑T, it is possible to cure patients.

This logic of “surgery + CAR‑T” for cure has already been validated over a longer time frame in hepatocellular carcinoma. Dr. Li mentioned two liver cancer patients treated in 2015: one patient, after interventional therapy for inferior vena cava tumor thrombus, still had an alpha‑fetoprotein (AFP) level of approximately 1,280 ng/ml. The team used a cautious step‑wise dosing strategy to complete one cycle of treatment, after which the biomarker normalized and no further medication was needed. With follow‑up now approaching 10 years, the patient is considered to have achieved “clinical cure.” Another patient with concurrent peritoneal lymph node metastasis also had AFP normalize and no recurrence after two cycles of CAR‑T combined with local gamma knife therapy.

Regarding other products targeting the same target (such as CLDN18.2 ADCs and monoclonal antibodies), Dr. Li’s logic is straightforward: as long as a drug has been validated by clinical data and approved, it proves that it is effective and qualifies as a “comrade‑in‑arms”on the battlefield. CAR‑T kills via T cells, while ADCs are essentially targeted chemotherapy—the mechanisms do not overlap. In his view, combination of various modalities is the more realistic treatment path for the future.

Next‑Generation Technologies: Universal CAR‑T and In Vivo CAR‑T

CARsgen has made a clear strategic choice regarding the next evolutionary direction of CAR‑T: the company has announced that it will no longer add new early‑stage autologous CAR‑T pipelines. For the autologous platform, it will only maintain indication expansion for its two approved products (zevorcabtagene autoleucel and satricabtagene autoleucel), while R&D resources are being heavily shifted toward universal CAR‑T and in vivo CAR‑T, two next‑generation technologies.

This shift is driven on one hand by the growing recognition of autologous CAR‑T’s practical limitations: in postoperative adjuvant settings, some patients progress before cell manufacturing is completed and cannot receive the infusion; in earlier‑line treatment settings, patients have often already received bispecific antibodies or monoclonal antibodies, and their T cells may be exhausted, making autologous cell manufacturing difficult. On the other hand, the universal technology platform itself has matured to the point of supporting this decision. At the 2026 European Hematology Association (EHA) annual meeting, the company presented positive data for two universal CAR‑T products at recommended doses: in the first‑in‑human trial of CT0596 (universal BCMA CAR‑T), 8 patients with relapsed/refractory multiple myeloma or primary plasma cell leukemia achieved a complete response rate of 75%; in the first‑in‑human trial of CT1190B (universal CD19/CD20 CAR‑T), 12 patients with large B‑cell lymphoma or follicular lymphoma achieved an objective response rate of 91.7% (11/12) and a complete response rate of 66.7% (8/12). Recently, two investigational new drug applications for CT0596 and CT1190B were approved by the National Medical Products Administration.

In vivo CAR‑T is an even earlier‑stage direction with greater conceptual potential. Compared with universal CAR‑T, its greatest advantage is the elimination of lymphodepletion preconditioning. Dr. Li believes autoimmune diseases will be its largest future application scenario, with the potential to achieve “over 50% of patients cured with a single infusion, with lifelong freedom from medication.” However, clinical challenges remain significant: for solid tumors, whether in vivo‑delivered CAR‑T can sufficiently infiltrate solid tumor tissue and produce efficacy; for intracranial tumors, low viral delivery efficiency and rapid renal clearance in vivo mean that treating intracranial tumors will require crossing the blood‑brain barrier; and in multiple myeloma, with bispecific antibodies now approved for earlier lines, whether in vivo CAR‑T will be effective in patients previously exposed to bispecifics requires further observation. He emphasized that universal CAR‑T and in vivo CAR‑T are not simply sequential iterations, but two parallel technology routes serving different clinical scenarios, and their respective positions will ultimately be validated by evidence‑based medicine.

Commercialization and the Future

Beyond the technical breakthroughs, the commercial launch of satricabtagene autoleucel is also drawing intense attention from the entire industry. In contrast to the company’s first autologous CAR‑T product zevorcabtagene autoleucel (autologous BCMA CAR‑T), whose sales were outsourced to Huadong Medicine, satricabtagene autoleucel is being commercialized by CARsgen’s own newly established sales team of nearly 50 people. Dr. Li cited several reasons: the product itself is relatively new, requiring tighter integration of pre‑launch medical education with post‑launch commercial promotion; the in‑house team enables deeper collaboration with commercial insurance providers—the product has already been included in ZhongAn Insurance’s million‑yuan medical insurance and Haoyibao’s commercial insurance products, and has passed the preliminary formal review for the 2026 National Commercial Health Insurance Innovative Drug Catalog; it also helps build team capabilities for future overseas market expansion. The company’s publicly disclosed sales target for this year is 200 orders. Given that market development time this year is only half a year, this figure is viewed as a “training exercise”.

For global expansion, CARsgen plans to pursue registrations in Hong Kong, Macau, and Singapore, while also preparing for the U.S. and European markets. Dr. Li acknowledged that regulatory environments vary greatly across regions: registration in Hong Kong, Macau, and Singapore is relatively straightforward; while U.S. and European regulatory policies still carry uncertainty, the product has already received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation from the FDA, and the European Medicines Agency has also granted Priority Medicines (PRIME) and Orphan Drug Product designations.

Closing Remarks

At the end of the interview, Dr. Li spoke of his hopes for the next decade: that universal CAR‑T will truly become accessible to ordinary people by 2030; that more patients will achieve genuine cure, not just extended survival; and that the ultimate vision is to make cell therapy a “single infusion, lifelong freedom from medication,” extending this concept beyond oncology to autoimmune diseases. He recalled the five characters written on the flyleaf of a copy of Molecular Cloning he bought in the year he graduated—”Aspire to lofty goals”—a phrase that perhaps best captures the annotation of his more than a decade of venturing into uncharted territory.

0
0
Loading